Kenneth Fink, MD
Hematology · Charlotte, NCNPI 1205817558
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,067 of the $3,793 with a category attached, or 80.9%. It is spread thinly across 33 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology clinicians in NC, where the typical reported total is $12,876.
Across 151 payments — averaging $25.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$523
- Johnson & Johnson$501
- Daiichi Sankyo Inc.$410
- Genentech USA, Inc.$349
- Novartis$183
- Pfizer$183
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,06781%
- Education$72519%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 17 | $523 |
| Johnson & Johnson(2 entities) | 13 | $501 |
| Daiichi Sankyo Inc. | 11 | $410 |
| Genentech USA, Inc. | 16 | $349 |
| Novartis | 10 | $183 |
| Pfizer | 11 | $183 |
| Sanofi | 4 | $162 |
| Bristol Myers Squibb | 8 | $158 |
| Merck | 5 | $153 |
| Paratek Pharmaceuticals, Inc. | 1 | $125 |
| Seagen Inc. | 10 | $117 |
| Gilead(2 entities) | 7 | $103 |
| Boston Scientific | 1 | $100 |
| Incyte Corporation | 1 | $100 |
| Exelixis Inc. | 5 | $86 |
| Adaptive Biotechnologies Corporation | 2 | $55 |
| AstraZeneca(2 entities) | 3 | $51 |
| Beigene USA, Inc. | 3 | $49 |
| Deciphera Pharmaceuticals Inc. | 2 | $47 |
| Lexicon Pharmaceuticals, Inc. | 3 | $40 |
| Regeneron Healthcare Solutions, Inc. | 2 | $37 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $35 |
| Astellas Pharma US Inc | 2 | $30 |
| Eisai Inc. | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Boehringer Ingelheim | 1 | $24 |
| Springworks Therapeutics, Inc. | 1 | $19 |
| Sobi, Inc | 1 | $18 |
| Beone Medicines USA, Inc. | 1 | $17 |
| GSK | 1 | $16 |
| Servier Pharmaceuticals LLC | 1 | $16 |
| Secura Bio, Inc. | 1 | $16 |
| Novo Nordisk | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPDIVO$233
- ELITEK$125
- XARELTO$125
- NUZYRA$125
- GENERAL VASCULAR INTERVENTION$100
How this compares
$3,793 in reported general payments places this provider in the 35th percentile of 65 hematology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 58 | $871,245 |
| RevlimidLenalidomide | 21 | $370,426 |
| TasignaNilotinib Hcl | 23 | $324,006 |
| VenclextaVenetoclax | 25 | $300,018 |
| XtandiEnzalutamide | 20 | $262,632 |
| XareltoRivaroxaban | 153 | $118,021 |
| Abiraterone Acetate | 66 | $67,692 |
| OxycontinOxycodone Hcl | 11 | $9,264 |
| Tamoxifen Citrate | 94 | $3,052 |
| Anastrozole | 62 | $1,639 |
| Hydroxyurea | 51 | $1,638 |
| Anagrelide Hcl | 18 | $1,438 |
| Dutasteride | 70 | $1,342 |
| Gabapentin | 116 | $1,222 |
| Oxycodone Hcl | 61 | $1,007 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $158 | $370,42621 claims |
| NovartisTasigna | $183 | $324,00623 claims |
| Astellas Pharma US IncXtandi | $30 | $262,63220 claims |
| Johnson & JohnsonXarelto | $501 | $118,021153 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 65 hematology providers in North Carolina.
Other hematology in Charlotte
- Ryan JacobsCharlotte$1.5M
- Alan Zausner SkarbnikCharlotte$1.1M
- Raymond ThertulienCharlotte$561K
- Ruben MesaCharlotte$384K
- Michael GrunwaldCharlotte$344K
- Nilay ShahCharlotte$228K
- Peter VoorheesCharlotte$157K
- Patricia KropfCharlotte$122K
- Arielle HeekeCharlotte$88K
- Earle BurgessCharlotte$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.